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Summary Background: Tobacco smokers have lower serum levels of immunoglobulin
(Ig)G, mainly due to lower levels of IgG2, than non-smokers. The component(s) in
tobacco smoke responsible for this effect is unknown, but animal studies have
implicated nicotine as a major contributor to the immunologic effects of smoking.
Does nicotine exposure due to use of smokeless tobacco (oral moist snuff) or nicotine
replacement therapy influence serum Ig levels in humans?
Methods: Serum content of Ig classes and IgG subclasses was analysed in 77 non-
smoking nicotine consumers, including 48 users of oral moist snuff (smokeless tobacco
users) and 29 ex-smokers on nicotine replacement therapy, and compared with 44
healthy controls. Former smokers in any group had quit smoking at least 6 months
prior to study entry. Ig class and IgG subclass levels were determined by radial
immunodiffusion. Systemic nicotine exposure was excluded and confirmed by
measuring urine content of cotinine using a quantitative radioimmunoassay.
Results: Ig class and IgG subclass levels did not differ significantly between the
groups, with the sole exception of IgG4, which was significantly lower in nicotine
consumers than in healthy subjects (0.470.3 vs. 0.670.4 g/l, mean7SD, 95%
confidence interval {0.3;0.05}). There was no correlation between any Ig variable
and cotinine concentration.
Conclusions: The decreased levels of IgG and IgG2 seen in tobacco smokers do not
seem to be an effect of systemic exposure to nicotine.
& 2003 Elsevier Ltd. All rights reserved.
Introduction
Several large studies have shown that tobacco
smokers have lower levels of immunoglobulin (Ig)G
and IgA1–4 and higher levels of IgE5,6 than non-
smokers, changes that may contribute to the
propensity for respiratory infections seen in smo-
kers. Among the IgG subclasses, IgG2 levels are
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approximately 40% compared with non-smokers.7
This is of special interest since smoking is an
independent risk factor for invasive pneumococcal
disease,8 and antibodies directed towards bacterial
species commonly associated with respiratory
infections (Haemophilus influenzae and Strepto-
coccus pneumoniae) predominantly belong to the
IgG2 subclass.9,10
The mechanism(s) by which smoking affects
serum levels of Ig has not been clarified. There is
evidence of a dose–response relationship, with
lower levels of IgG with increased smoking.2,4
Furthermore, the effect appears to be reversible
after smoking cessation.2,11 The component(s) of
cigarette smoke responsible for the effect has not
been determined, but animal and in vitro studies
have implicated nicotine as a major factor.12,13
However, whether serum levels of immunoglobulins
are affected in non-smokers with systemic exposure
to nicotine in a similar manner to that seen in
smokers is not known. To date, no in vivo studies in
humans relating to this issue have been presented.
We therefore decided to perform a study of serum
Ig and IgG subclass levels in non-smokers (ex-
smokers or never-smokers) using oral moist snuff or
nicotine replacement therapy (NRT).
Materials and methods
Design
This is a cross-sectional, parallel group study of
serum Ig class and IgG subclass levels in nicotine
consumers (NC), either users of oral moist snuff
administered orally under the upper lip; smokeless
tobacco users (STU), or ex-smokers with daily NRT.
Healthy subjects with no exposure to nicotine
served as a control group (HC). Participants were
recruited by advertisements in two daily news-
papers. Study size was based on the results of a
previous study of the effect of smoking on serum
levels of Ig.7
The study was performed at the Sahlgrenska
University Hospital, G .oteborg, and the study pro-
tocol was approved by the local ethics committee
(Dnr S 26-01).
Study population
Subjects between 18 and 75 years of age were
eligible. The study group consisted of current users
of oral moist snuff, with or without a previous
history of habitual tobacco smoking, and of ex-
smokers who used nicotine on a daily basis by
means of a dermal plaster or chewing gum. Any
former tobacco smokers had to have quit smoking
more than 6 months before inclusion in the study.
The control group consisted of subjects who had
never used nicotine at all or whose use had ended
more than 6 months previously.
Subjects with diseases or medical treatments
known or thought to influence serum Ig-levels were
not included in the study. Accordingly, the following
exclusion criteria were chosen: pregnancy; chronic
liver or renal disease, diabetes mellitus, severe
cardiac failure, severe chronic lung disease, any
known immunodeficiency or rheumatologic disease;
history of bronchial asthma, allergy or atopy;
symptoms of infectious disease with pyrexia or
any use of antibiotics, antihistamines or N-acet-
ylcysteine during 4 weeks prior to the investigation.
In addition, subjects with any use of steroids
including oestrogen hormone substitution or any
other immunomodulating treatment or vaccination
during 2 months prior to the investigation were
excluded.
Clinical examination and performance
Following an interview to ensure that all inclusion
and no exclusion criteria were fulfilled, all subjects
gave written detailed information of smoking
history, use of snuff and NRT.
All subjects provided a 10ml sample of venous
blood, and a 10ml urine sample. All samples where
taken between 7 am and 10 am. Serum was sepa-
rated, frozen and stored at 201C awaiting further
analysis. Urine samples were frozen and stored
similarly. The study was performed between May
and December 2001.
Determination of nicotine exposure
Systemic exposure to nicotine was assessed by a
radioimmuno assay (RIA) with a double antibody for
cotinine; a major metabolite of nicotine, the urine
levels of which has been shown to accurately
reflect systemic exposure to nicotine.14,15 A com-
mercially available kit, Nicotine Metabolite Double
Antibody DPC KTCD1, was used according to the
instructions of the manufacturer (Diagnostic Pro-
ducts Corporation, Los Angeles, CA, USA). The
qualitative cut off for a positive sample, i.e.
systemic exposure to nicotine, with this RIA was
2.0 mmol/l. The technical upper limit according to
the standard-curve corresponded to a concentra-
tion of 85 mmol/l. Higher values in a test sample
were assigned this value. Subjects in the control
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group had to have concentrations lower than
2.0 mmol/l.
Assay of serum immunoglobulins
The content of IgG, IgM and IgA as well as IgG
subclasses in serum was assessed by radial immu-
nodiffusion as previously described.7 For the
definition of Ig class and IgG subclass deficiency,
the class reference ranges of the department of
Clinical Immunology (IgG 7.6–22.1 g/l, IgM 0.5–
3.4 g/l and IgA 0.2–2.8 g/l) and the IgG subclass
ranges published by Oxelius16 (IgG1 4.22–12.92 g/l,
IgG2 1.17–7.47 g/l, IgG3 0.41–1.29 g/l and
IgG4o2.91 g/l) were used. The serum content of
IgE was assessed using the ImmunoCAPt method
and the UniCAPt kit of Pharmacia & Upjohn
(Uppsala, Sweden) according to the instructions
from the manufacturer. The result is given in units/
ml with one unit corresponding to 2 ng. The upper
limit for a normal concentration is 337 U/ml.
Statistical considerations
Most demographic and clinical data did not show a
normal distribution and are presented as median
values and ranges. For comparisons between groups
of non-parametric data, the Mann–Whitney U-test
or the w2 test with continuity correction according
to Yates17 were used, as appropriate. Confidence
intervals for the difference between median values
were calculated according to Hollander and
Wolfe.18 With the exception of IgE, immunoglobulin
and cotinine data showed approximate normal
distributions, and accordingly parametric methods
were used. These data are presented as mean7SD.
A Pearson or Spearman rank correlation coefficient
was calculated to analyse correlations between




A total of 125 recruited subjects were included and
completed the study. Results from four subjects
were subsequently excluded from final data analy-
sis for the following reasons:
Two men in the control group had a complete
IgA deficiency with a compensatory increase in
IgG1 concentration. This condition is well recog-
nized as the most common primary immunodefi-
ciency in a caucasian population.19 One man in the
control group had a high concentration of cotinine
in urine (66 mmol/l). Finally, one man in the study
group had no detectable cotinine in his urine
sample.
Demographic and clinical data from the remain-
ing 121 subjects, 77 NC, including 48 STU and 29
NRT, and 44 HC are presented in Tables 1 and 2.
Gender as well as age distribution were similar in
the two groups. Most controls (64%) were
never-smokers while the opposite (83% ex-smokers)
was true in the study group. Ex-smokers in the HC
group had on average quit smoking longer ago and
had smoked less than ex-smokers in the study
group. In NC (Table 2) both the proportion of
women and median age were higher in the NRT
group.
Systemic nicotine exposure
STU had significantly higher levels of cotinine in
urine than NRT. The correlation between consump-
tion of nicotine containing products and cotinine
levels in urine was investigated in the NRT and STU
groups, respectively. The scattergram (not shown)
revealed a reasonably strong correlation between
daily dose of nicotine and cotinine in urine in the
NRT group (Spearman; r 0.49, P ¼ 0:009). In STU
ARTICLE IN PRESS






Male/female 35/42 20/24 NS F
Age (years) 44 (20–75) 43 (22–65) NS F
Number (%) of ex-smokers 64 (83) 16 (36) o0.001 (30; 65)
Time since smoke-quittingn (years) 5 (0.5–20) 13 (1–25) o0.001 (13;3)
Packyearsn 20 (2–78) 8 (1.5–32) o0.05 (2.3;16.5)
Data are presented as median values with ranges in parenthesis. CI: confidence interval for the difference between groups.
NS¼ not significant.
nEx-smokers only.
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the correlation was weaker (Spearman; r 0.36,
P ¼ 0:015).
Serum immunoglobulins and nicotine
exposure
Immunoglobulin class and IgG subclass data are
shown in Table 3. Mean differences in serum levels
between the groups were small and with the
exception of IgG4, which was significantly lower
in the NC group, not statistically significant. Since
the effect of smoking on Ig levels were found to be
stronger in women than in men in a previous study7
women in each study group was compared sepa-
rately. There were no significant differences for any
Ig class or subclass between women in the NC and
HC groups. The number of subjects with Ig or IgG
subclass deficiency, as previously defined, is shown
in Table 4. There were no stastistically significant
differences in proportions between the groups.
Within the NC group, subjects on NRT had
significantly lower levels of IgG compared with
the STU subgroup (9.571.9 vs. 11.172.2 g/l, mean
difference 1.6 g/l, 95% CI [2.6; 0.6]). There
were no other significant differences between the
two subgroups of nicotin consumers, either of Ig
and IgG subclass levels, or of the fraction of
subjects with Ig and IgG subclass deficiencies.
According to scattergrams (not shown) there was
no apparent correlation between urine levels of
cotinine and serum levels of any Ig variable in NC.
All Pearson correlation coefficients were lower than
0.25.
Discussion
In this study we found only small and, with the
exception of IgG4, insignificant differences be-
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Male/female 9/20 26/22 o0.05 (45;1)
Age (years) 53(30–70) 39(20–75) o0.001 (9;20)
Tobacco consumption (g/week) F 88(12–525) F F
NRT dose (mg/day) 26(10–70) F F F
Cotinine in urine (mmol/l)* 25716 37721 o0.05 (21;3)
Data are presented as median values with ranges in parenthesis with the exception of (*) where mean7SD are shown. NRT:
nicotine replacement therapy. CI: confidence interval for the difference between the groups.





Mean difference 95% CI
IgG (g/l) 10.572.2 10.672.0 0.13 (0.9;0.7)
IgA (g/l) 2.571.1 2.370.8 0.21 (0.2;0.6)
IgM (g/l) 1.470.7 1.670.6 0.19 (0.4;0.1)
IgG1 (g/l) 5.671.6 5.971.9 0.26 (0.9;0.4)
IgG2 (g/l) 3.471.0 3.671.1 0.25 (0.6;0.2)
IgG3 (g/l) 0.670.3 0.670.2 0.02 (0.1;0.1)
IgG4 (g/l) 0.470.3 0.670.4 0.18 (0.3;0.05)
IgE (U/ml)* 17 (0–580) 25 (2–253) 3** (10;4)
Immunoglobulin data are presented as mean7SD with the exception of (*) where median values with ranges in parenthesis are
shown. CI: confidence interval for the difference between the groups. (**) Median difference between groups.
Table 4 Number (%) of subjects with immunoglo-
bulin deficiency according to Oxelius16 in nicotine
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tween subjects with chronic nicotine exposure and
subjects with no recent exposure. Although Ig
levels did not differ much between the groups,
there was a tendency towards lower levels in NC in
all the measured Ig variables. While we cannot
exclude that these small differences are the result
of nicotine exposure, the relations between coti-
nine concentrations and levels of different Ig
variables contradicts this possibility. This was found
to be true also for IgG4, the only IgG subclass that
was significantly lower in NC. These findings are in
contrast with studies in smokers, where a clear
dose–response relationship between daily cigarette
consumption and IgG levels was found in two large
studies.2,4 Whether the difference in IgG4 levels
between the groups is a chance finding or an effect
of nicotine exposure is unclear but the lack of a
dose–response relationship favours the first inter-
pretation. In short, nicotine does not seem to
contribute to the effect on serum Ig levels that we
see in smokers.
When analysing data, the issue of a possible
gender difference was of particular interest to us.
However, we found no indication of this when
women and men in study and control groups were
compared separately. Thus, the greater effect of
smoking on serum levels of IgG and IgG2 in women
than in men that we reported previously, was not
found in non-smoking women consuming nicotine in
this study.7
In previous in vitro studies, primarily in rodents,
nicotine has been shown to have immunosuppres-
sive effects. Both decreased proliferative response
of T-lymphocytes and decreased induction of anti-
body-forming cells after stimulation with anti-CD3
have been described (reviewed by McAllister-Sistilli
and co-workers13). However, in the only in vivo
study in humans that we have found, use of
nicotine-containing chewing gum in ex-smokers
who recently quit smoking did not influence
salivary levels of secretory IgA.20 In the present
study previous findings in laboratory animals was
not confirmed. There are at least two possible
explanations for this discrepancy. First, different
doses of nicotine. In animal studies where nicotine
exposure was found to significantly impair T-cell
function, nicotine exposure was carefully adjusted
to correspond to that of smokers of 20–40 cigar-
ettes per day.21,22 However, in a study where
nicotine was found to completely inhibit antibody
response from rabbit spleen cells, nicotine levels
were 1000-fold higher than those found in smo-
kers.12 Secondly, the duration of nicotine exposure
is important. In humans the plasma half-time of
nicotine is only approximately 30min,23 and
although the main metabolite cotinine has a much
longer half-time, its biological activity on human
cells is only 1% of that of nicotine.24 In vitro, there
is no conversion of nicotine to cotinine, and the
experimental conditions in the referred studies are
thus not comparable with in vivo exposure to
nicotine in humans.
It is possible that the tendency towards lower
serum Ig levels we see in NC is a lingering effect of
smoking. We chose 6 months of smoking abstinence
as a minimum requirement for participation in the
study, which according to previous studies is ample
time after smoke-quitting for changes in serum
immunoglobulin levels induced by smoking to
revert to almost normal compared with never-
smokers.2,4,11 However, time since smoke-quitting
was substantially longer in the 16 ex-smokers from
the control group than in the 64 ex-smokers in the
NC group and the proportion of ex-smokers in each
group also differed (Table 1). Furthermore, com-
parison of the two subgroups of NC revealed that
IgG was significantly lower in the NRT group with
higher historic tobacco consumption (packyears,
data not shown) and containing no never-smokers,
than in the STU group. For these reasons, it is
possible that the small difference we see between
the study groups (NC and HC) is a lingering effect of
previous tobacco smoking.
Another interesting point is that the overall
results were similar both in subjects on NRT and
in STU. Nicotine-containing chewing gums or
dermal plasters contain no other chemical with
potential immunological effect than nicotine. Oral
moist snuff, on the other hand, is a smokeless
tobacco product, which in addition to nicotine
contains a large number of chemical substances,
many of which exert toxic effects.25,26 Use of this
product exposes the organism to many more toxic
substances than nicotine. However, our results
indicate that this form of tobacco use has no effect
on serum Ig levels and consequently that exposure
to inhaled tobacco smoke but not tobacco products
per se is necessary for this particular immunologic
effect to occur.
The fact that we did not include a control group
of smokers might be considered a drawback with
the study. However, the literature offers over-
whelming proof of the association between tobacco
smoking and decreased levels of IgG. Our aim was
to study the possible effect of nicotine and with
this aim we feel that the design, enabling a
comparison between a group with verified chronic
exposure to nicotine and a group in which recent
nicotine exposure could be excluded, was appro-
priate. The crucial issue is whether the degree of
systemic exposure to nicotine in our study group is
comparable with that seen in tobacco smokers.
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There are good reasons to believe that this is the
case. First, several reports from other researchers
have shown that nicotine and cotinine levels in
both plasma and urine are comparable or higher in
users of smokeless tobacco27–29Fand more speci-
ficallyFusers of Swedish oral moist snuff30,31 than
in smokers. Secondly, urine cotinine levels in our
study population of NC were on average higher than
those reported in tobacco smokers in a study using
the same radioimmunoassay that we did.32 It is
therefore highly unlikely that low nicotine expo-
sure is the reason why no effect on serum Ig levels
was found in our NC group.
To conclude, in this study we found no relation
between systemic exposure to nicotine and serum
levels of immunoglobulins. This was true irrespec-
tive of whether nicotine was administered in the
form of chewing gum, dermal plaster or in the form
of smokeless tobacco products. Our results make it
highly unlikely that the nicotine content of tobacco
smoke is a major contributor to the reduction in
serum IgG and IgG2 levels seen in smokers.
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